Khosroshahi H T, Tubbs R S, Shoja M M, Ghafari A, Noshad H, Ardalan M R
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Transplant Proc. 2008 Jan-Feb;40(1):137-9. doi: 10.1016/j.transproceed.2007.12.016.
During kidney transplantation, the first contact between the recipient's immune system and the donor organ takes place immediately following the arterial anastomosis. The aim of this study was to evaluate the efficacy of a single, low-dose anti-thymocyte globulin (ATG) prophylaxis in the reduction of early acute rejection in renal allograft recipients.
In a randomized, controlled clinical trial, we studied the rate of acute rejection within the first month of kidney transplantation in patients who had received their transplant at a single center between the years 2004 and 2007. The patients were divided into 2 groups: group 1 (n = 37) received cyclosporine, mycophenolate mofetil or azathioprine, and prednisolone; group 2 (n = 31) received the above-mentioned agents plus a single ATG bolus (Thymoglobulin; SangStat, Lyon, France; 4-5 mg/kg) the night before the transplantation ( approximately 12 hours before the operation). Blood urea and serum creatinine levels were measured regularly in the posttransplantation period. Acute allograft rejection was justified clinically and/or pathologically. Statistical analysis was performed by SPSS 13.0 using Student t test and Fisher exact test. A P value < or = .05 was considered to indicate statistical significance.
There were no significant differences regarding the age and gender ratio between the 2 groups. Acute allograft rejection was found in 32.4% (n = 12) of group 1 patients, and was reduced to 12.9% (n = 4) in group 2 (P = .05). Hence, the first-month acute rejection episodes decreased by approximately 60% with ATG prophylaxis in renal transplant recipients.
Prophylactic administration of a single and low-dose ATG the night before kidney transplantation could reduce the risk of acute allograft rejection in renal transplant recipients. However, further studies with a greater number of patients should be conducted to confirm these results.
在肾移植过程中,受体免疫系统与供体器官的首次接触在动脉吻合后立即发生。本研究的目的是评估单次小剂量抗胸腺细胞球蛋白(ATG)预防措施在降低肾移植受体早期急性排斥反应方面的疗效。
在一项随机对照临床试验中,我们研究了2004年至2007年间在单一中心接受肾移植的患者在肾移植后第一个月内的急性排斥反应发生率。患者被分为两组:第1组(n = 37)接受环孢素、霉酚酸酯或硫唑嘌呤以及泼尼松龙治疗;第2组(n = 31)在移植前一晚(手术前约12小时)接受上述药物加单次ATG大剂量注射(即胸腺球蛋白;法国里昂赛斯塔尔公司生产;4 - 5毫克/千克)。在移植后的时期定期测量血尿素和血清肌酐水平。急性移植排斥反应通过临床和/或病理诊断来确定。使用SPSS 13.0软件进行统计分析,采用学生t检验和Fisher精确检验。P值≤0.05被认为具有统计学意义。
两组在年龄和性别比例方面没有显著差异。第1组患者中有32.4%(n = 12)发生急性移植排斥反应,而第2组降至12.9%(n = 4)(P = 0.05)。因此,在肾移植受体中,采用ATG预防措施可使第一个月的急性排斥反应发生率降低约60%。
肾移植前一晚预防性给予单次小剂量ATG可降低肾移植受体急性移植排斥反应的风险。然而,应进行更多患者参与的进一步研究以证实这些结果。